Drug intelligence / Profile preview

Dizoltec

Development stage: Preclinical
Lead developer: Jinan Yijunsheng Medical Service
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Vaginal

Overview

Dizoltec is a vaginal gel indicated for the control of recurrent vaginitis. It is utilized as part of a sequential therapy designed to reconstruct the vaginal microecology. The specific active ingredients and detailed mechanism of action beyond modulating the vaginal microbiome are not publicly available from the provided context.

Brand names: Dizoltec

Beyond the preview

Go deeper on Dizoltec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dizoltec.

Explore the full profile